Natera, Inc. Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera™ Patients with Stage II-III Colorectal Cancer
January 09, 2020 at 09:05 am EST
Share
Natera, Inc. announced a nationwide multi-center registry study called BESPOKE CRC for patients diagnosed with Stage II-III colorectal cancer (CRC). The study's objective is to measure the clinical impact of serial blood-based testing with Signatera, Natera's personalized and tumor-informed test for molecular residual disease (MRD) assessment, earlier relapse detection, and better patient risk stratification after surgery The BESPOKE CRC study will prospectively enroll 1,000 or more patients at time of surgery. Signatera testing will be performed multiple times in the first 6 months after surgery to help inform the need for adjuvant chemotherapy, and then approximately every 3 months in the surveillance setting to detect relapse early and enable more curative interventions. Patients will be followed for up to two years, to measure treatment changes and patient outcomes. The study will begin enrollment in early 2020, and it is expected to complete in 2023.
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of womenâs health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâs algorithms and bioinformatics in order to validate and launch tests based on the Companyâs technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.